UK Grants Marketing Authorization for Novartis’ Radioligand Therapy for Advanced Prostate Cancer

The UK’s MHRA has granted marketing authorization for Novartis’ radioligand therapy, Pluvicto, for the treatment of advanced prostate cancer in Great Britain.